Isaac Manke - 18 Mar 2026 Form 3 Insider Report for Addex Therapeutics Ltd. (ADXN)

Role
Director
Signature
/s/ Lenaic Nathanael Teyssedou by power of attorney
Issuer symbol
ADXN
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 11:06:22 UTC
Previous filing
02 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Manke Isaac Director 405 DORADO BEACH EAST, DORADO /s/ Lenaic Nathanael Teyssedou by power of attorney 18 Mar 2026 0001622769

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ADXN Common Stock 219,561 18 Mar 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ADXN Stock-option (Right to Buy) 18 Mar 2026 Common Stock 50,000 $0.0640 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents 219,561 shares of Common Stock listed on SIX Swiss Exchange.
F2 The stock-options vest on equal monthly installments over a 4-year period beginning at the exercisable date. Each stock-option grants to right to purchase one ADXN share listed on SIX Swiss Exchange.
F3 The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $ 1.2769 per CHF 1.00 as of March 12, 2026.

Remarks:

Exhibit List : Exhibit 24 - Power of Attorney